Evidence-Based Complementary and Alternative Medicine

Review Article

Sanqi Panax Notoginseng Injection for Angina Pectoris

Table 1

The characteristics of included RCTs of Sanqi Panax Notoginseng injection for AP.


Study ID	Sample	Type of angina	Diagnosis standard	Age	Intervention group	Control group	Course (week)	Outcome measures

Liu et al. 2003 [21]	146	UAP	1979 ISFC/WHO	46–74	SPN + conventional drugs	Conventional drugs	2	RAS, ECG, DAA
Guo 2010 [22]	100	SAP	1979 ISFC/WHO	40–82	SPN	Isosorbide mononitrate	2	RAS, ECG, BL, adverse event
Chen et al. 2004 [23]	143	SAP	1979 ISFC/WHO	45–79	SPN SPN + isosorbide mononitrate	Isosorbide mononitrate	3	RAS, ECG,, BL, adverse event,
Ji and Fan 2003 [24]	78	AP	GCRNDTCM	49–83	SPN + conventional drugs	Conventional drugs	2	RAS, ECG, adverse event
Ruan 2010 [25]	150	SAP	GCRNDTCM	44–71	SPN SPN + isosorbide mononitrate	Isosorbide mononitrate	2	RAS, ECG, adverse event Follow-up
Li 2009 [26]	80	UAP	GCRNDTCM	18–80	SPN + conventional drugs	Conventional drugs	4	RAS, ECG, BL, CRP, adverse event
Li 2009 [27]	80	UAP	1979 ISFC/WHO	46–74	SPN + conventional drugs	Conventional drugs	4	RAS, ECG, FAA, adverse event
Zong et al. 2009 [28]	80	AP	1979 ISFC/WHO	51 ± 11	SPN + conventional drugs	Conventional drugs	2	RAS, ECG, BL
Li et al. 2011 [29]	72	SAP	1979 ISFC/WHO	66 ± 8	SPN	Nitroglycerin	2	RAS, ECG, adverse event
Gao et al. 2011 [30]	40	UAP	1979 ISFC/WHO	52 ± 8	SPN + conventional drugs	Conventional drugs	2	RAS, ECG, CRP,

SPN: Sanqi Panax Notoginseng injection; RAS: reduction of angina symptoms; FAA: frequency of angina attack; DAA: duration of angina attack; GCRNDTCM: Guidelines of Clinical Research of New Drugs of Traditional Chinese Medicine; BL: blood lipid; CRP: C-reative protein.